Announcement PDF ASX Announcement – 21 February 2025 HALF-YEAR RESULTS CONFERENCE CALL DETAILS Resonance Health Limited (Resonance or Company) (ASX: RHT) intends to announce its half-year results for the 6 months to 31 December 2024, on the Australian Securities Exchange (ASX) platform on or before 28 February 2025. The Company is pleased to advise that its Chief Executive Officer and Chief Financial Officer will be hosting a conference call for investors and analysts, at 1:00 p.m. AEDT (12:00 p.m. AEST) (10:00 a.m. AWST) on Friday, 28 February 2025. Access to the conference call is by pre-registration via Chorus Call. Following pre-registration participants will be provided a calendar invite with dial-in and web browser access links to join the call. Participants can lodge questions on the chorus platform either prior to or during the call. Full details of the call and the link for pre-registration are as follows: Event: Half-Year Results Call Presenters: Resonance Health CEO and CFO Time: 1:00 p.m. AEDT (12:00 p.m. AEST) (10:00 a.m. AWST) Date: 28 February 2025 Registration: https://ccmediaframe.com/?id=Rzvjsmyj This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact: Andrew Harrison, CEO E: andrewh@resonancehealth.com P: +61 (0)8 9286 5300 About Resonance Health Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development. The Company’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include: Resonance Health Ltd ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com § FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through noninvasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment. § FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®. § HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease. § HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liverfat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease. § LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFatAI® into a consolidated report providing accurate assessment of LIC and liver fat. § CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared. The Company has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising noninvasive MRI analysis. The Company also operates Clinical Trial Management (CRO Services) and Clinical Trial Site (TrialsWest) businesses that cater to global clinical trial customers. Clinicians, patients, and shareholders are encouraged to register interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn. Page 2